Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab-800CW fluorescence imaging in inflammatory bowel disease, rheumatoid arthritis, and spondyloarthritis
NL-OMON56363Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of adalimumab in inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthritis (SpA) (3 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Safety of adalimumab-800CW and Feasibility of fluorescence imaging. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)rheumatoid arthritis (RA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on NL-OMON56363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56363.